Low risk, with a 2% risk of metastasis within 5 years.
Intermediate risk, with a 21% risk of metastasis within 5 years.
High risk, with 72% risk of metastasis within 5 years.
The National Comprehensive Cancer Network (NCCN), a group of the most recognized and respected comprehensive cancer centers in the U.S., evaluated the DecisionDx-UM test and included it in its first ever clinical guidelines for uveal melanoma in 2018. The NCCN guidelines include the DecisionDx-UM test result as a prognostic method for determining risk of metastasis and recommend different metastatic surveillance regimens based on a Class 1A, 1B, and 2 result.
In addition, the American Joint Committee on Cancer (AJCC, version 8, 2018) recommends gene expression profile testing as part of clinical care because the results are “clinically significant.” DecisionDx-UM is the only clinically available gene expression profile test for use in uveal melanoma in the U.S.